Figure 1 Jouvex Property-Location in Abitibi Figure 2 Jouvex-Diamond Drill Program 2026 Figure 3 Mag Survey- First Vertical Derivative Figure 4 Jouvex-DDH 2026-Geophysics MONTREAL, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of a 1,600-metre drilling program on its Jouvex gold property, wholly owned by Midland and located approximately 10 kilometres northwest of the Douay deposit. Exploration work resumed on the Jouv ...

Core Insights - Midland Exploration Inc. has announced the results of its 2025 drilling campaign for lithium on the Galinée project, which is located near the Adina lithium deposit [7][19] - The drilling program included a total of 14 diamond drill holes and 9 reverse circulation drill holes, totaling 4,105.09 meters, with significant lithium and cesium mineralization identified [9][11] Drilling Results - The best lithium results from the 2025 drilling program include: - 1.14% Li2O over 30.59 meters, including 1.77% Li2O over 18.39 meters (hole TLIB0051) - 0.53% Li2O over 22.90 meters, including 1.09% Li2O over 6.10 meters (hole TLIB0044) - 1.08% Li2O over 17.10 meters (hole TLIB0034) [11][12] - New cesium mineralization was identified with results such as: - 9.15% Cs2O over 6.40 meters (hole TLIB0006) - 1.89% Cs2O over 12.10 meters (hole TLIB0044) [11][13] Geological Observations - The Galinée project exhibits two distinct styles of lithium mineralization: - The Iceberg area features a stacked spodumene pegmatite system that is 10 to 20 meters thick - South of Iceberg, the pegmatites are generally less than 10 meters thick and laterally extensive [15][16] - The Iceberg spodumene pegmatite bodies remain open along strike and to depth, indicating potential for further exploration [16] Project Background - The Galinée project is strategically located approximately 5 kilometers east of the Adina deposit, which has significant mineral resources [19] - Midland has a partnership with Rio Tinto Exploration Canada Inc. (RTEC) under an option agreement, with RTEC recently paying $487,500 as part of this agreement [20] Future Plans - Further drilling is planned to better define the geometry and extension of the lithium pegmatites identified in the current drilling campaign [16]

Core Insights - Pediatrix Medical Group, Inc. (MD) is positioned for growth due to increased collection activity, improved patient acuity, higher contract administrative fees, a favorable payor mix, and strategic acquisitions [1][10] - MD's shares have increased by 55.2% over the past six months, significantly outperforming the industry average of 6.7% [1][10] Company Overview - Pediatrix Medical has a market capitalization of $1.8 billion and offers various physician services in newborn, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties [2] - The company's forward P/E ratio is 10.35X, which is lower than the industry average of 17.93X, and it holds a Value Score of B [2] Earnings Estimates - The Zacks Consensus Estimate for MD's 2025 earnings is $2.07 per share, reflecting a year-over-year increase of 37.1% [3] - The revenue consensus for 2025 is projected at $1.9 billion, with MD having beaten earnings estimates in the past four quarters by an average surprise of 35.4% [3] Growth Drivers - MD is experiencing growth in same-unit revenues and pricing, supported by an improved payer mix, solid revenue cycle management (RCM) cash collections, increased patient acuity, and higher administrative fees from hospital contracts [4] - In Q3 2025, same-unit revenues from net reimbursement-related factors rose by 7.6% year-over-year [5] Financial Performance - MD has raised its adjusted EBITDA guidance for 2025 to a range of $270-$290 million, up from the previous range of $245 million to $255 million [5] - Total operating expenses decreased by 11% year-over-year in Q3 2025, with projections suggesting a nearly 19.5% decline in 2025 due to lower practice salaries and benefits [5] Strategic Initiatives - The company is expanding its telehealth services to enhance healthcare access and improve patient outcomes [6] - MD is actively pursuing mergers and acquisitions in core service lines, having acquired several practices for $19.2 million in September 2025 [7] Cash Flow and Share Repurchase - Net cash generated from operations in Q3 2025 was $138.1 million, an increase from $95.7 million a year ago [8] - In August 2025, MD authorized a $250 million share repurchase program and repurchased $20.9 million worth of shares in Q3 2025 [8] Debt Situation - As of September 30, 2025, MD had a net debt of $602.5 million, significantly higher than its cash balance of $340.1 million, which may pressure interest expenses [11] - The total debt-to-EBITDA ratio stands at 8.1%, well above the industry average of 2.4%, limiting financial flexibility [11]

Core Points - Midland Exploration Inc. has completed a non-brokered private placement, issuing a total of 4,972,876 flow-through shares at $0.56 each and 550,000 common shares at $0.46 each, raising total gross proceeds of $3,037,811 [1][2] - Centerra Gold Inc. has exercised its right to maintain approximately 9.9% ownership by acquiring 550,000 shares as part of the private placement [2] - Insiders participated in the private placement, acquiring 443,500 flow-through shares for total gross proceeds of $348,360, which is classified as a related party transaction [3] - Following the private placement, Midland has 112,973,453 common shares issued and outstanding, and the transaction is subject to final acceptance by the TSX Venture Exchange [4] Financial Details - The total gross proceeds from the private placement amount to $3,037,811, with $348,360 raised from insider participation [1][3] - Finder's fees totaling $116,485 were paid to third parties in connection with the private placement [4] Company Strategy - Midland plans to use the proceeds from the private placement to fund exploration activities on its properties in Quebec and for general corporate purposes [2] - The company is focused on discovering new world-class deposits of gold and critical metals in Quebec and aims to build its portfolio through partnerships and additional agreements [5]

Core Insights - Midland Exploration Inc. and SOQUEM Inc. announced positive results from the 2025 exploration campaign on the Nachicapau project, highlighting the discovery of a major hydrothermal system with high-grade copper, gold, and silver [3][4][19] Exploration Results - The 2025 sampling campaign lasted 9 days in September, collecting 213 rock samples, with 23 samples showing grades greater than 0.10% Cu, including 11 samples exceeding 1.00% Cu, with the highest at 13.70% Cu [5][7] - Significant gold grades were also identified, with values reaching up to 4.83 g/t Au, and silver grades up to 65.40 g/t Ag [5][7] - Six new mineralized showings were discovered, with notable grades including 4.66% Cu, 0.20 g/t Au, and 13.8 g/t Ag associated with disseminated chalcopyrite mineralization [7][13] Geological Context - The new mineralized showings are associated with veins hosting digenite, bornite, and malachite, with four showings exhibiting gold contents above 1.00 g/t Au, indicating a favorable metallotect for future exploration [12] - The spatial distribution of these showings spans nearly 2.7 km along the contact between mafic rocks and dolomites, suggesting significant exploration potential [12] Induced Polarization Survey - An OreVision® induced polarization survey was conducted over 20.45 km, revealing several anomalies that are currently under analysis to determine the best drill-testing strategy for future exploration phases [15][16] Strategic Alliance - The Strategic Alliance between Midland and SOQUEM aims to explore the mineral potential of the Labrador Trough, with a commitment of up to $5 million over four years, including a $1 million annual budget for 2025 [19][20]

Core Viewpoint - Pediatrix Medical Group (MD) has shown strong stock performance, with a 36.6% increase over the past month and an 81.6% gain since the start of the year, outperforming the Zacks Medical sector and Zacks Medical Services industry [1][2]. Financial Performance - The company has consistently exceeded earnings expectations, reporting an EPS of $0.67 against a consensus estimate of $0.46 in its last earnings report [2]. - For the current fiscal year, Pediatrix Medical Group is projected to achieve earnings of $2.06 per share on revenues of $1.91 billion, reflecting a 36.42% increase in EPS but a 5.04% decrease in revenues [3]. - The next fiscal year is expected to see earnings of $2.08 per share on revenues of $1.98 billion, indicating a year-over-year change of 0.68% in EPS and 3.33% in revenues [3]. Valuation Metrics - The stock trades at 11.6 times the current fiscal year EPS estimates, below the peer industry average of 16 times [7]. - On a trailing cash flow basis, it trades at 13.5 times compared to the peer group's average of 10.1 times, suggesting it is not among the top value stocks [7]. Zacks Rank and Style Scores - Pediatrix Medical Group holds a Zacks Rank of 1 (Strong Buy) due to a favorable earnings estimate revision trend [8]. - The company has a Value Score of B, a Growth Score of B, and a Momentum Score of A, resulting in a combined VGM Score of A [6][9]. Competitive Landscape - In comparison to industry peers, Progyny, Inc. (PGNY) also shows strong performance with a Zacks Rank of 2 (Buy) and similar style scores [10]. - PGNY is expected to post earnings of $1.93 per share on revenues of $1.27 billion for the current fiscal year, having beaten consensus estimates by 15.38% last quarter [11].

Core Viewpoint - Pediatrix Medical Group, Inc. (NYSE:MD) is identified as a promising small-cap stock, with a price target increase from $17 to $24 by Truist Financial, maintaining a Buy rating [1]. Financial Performance - The company experienced a 33.59% increase in share price following the release of its fiscal Q3 2025 results, which showed quarterly revenue of $492.88 million, a decrease of 3.58% year-over-year, but exceeding analysts' estimates by $16.43 million [2]. - Earnings per share (EPS) for the quarter was $0.67, surpassing consensus estimates by $0.20 [2]. Revenue Analysis - The revenue decline was attributed to a portfolio restructuring activity costing approximately $54 million. However, this was mitigated by an 8% growth in same-unit performance, a 7.5% increase in same-unit pricing, and a 40 basis points rise in patient service volumes [3]. EBITDA and Guidance - Adjusted EBITDA for the quarter reached $87 million, exceeding management's expectations, driven by positive pricing outcomes, collections, and expense controls [4]. - The company raised its full-year adjusted EBITDA guidance to a range of $270 million to $290 million, up from the previous range of $245 million to $255 million [4]. Company Overview - Pediatrix Medical Group, Inc. is a leading provider of specialized physician services for women, babies, and children, focusing on newborn, maternal-fetal, and pediatric subspecialty care [5].

Core Viewpoint - Midland Exploration Inc. has signed a definitive option agreement with Barrick Mining Corporation for the Lewis gold property, allowing Barrick to acquire up to a 75% interest in the property through cash payments and exploration work [1][2]. Option Agreement Details - Barrick can acquire a 75% interest in the Lewis property by making total cash payments of $750,000 and funding exploration work of $12,000,000 by December 31, 2032 [2]. - An initial 51% interest can be earned by Barrick through a cash payment of $250,000 and funding at least $3,000,000 in exploration work, including a guaranteed $200,000 by December 31, 2028, leading to a joint venture [3]. - An additional 9% interest can be earned by making cash payments of $200,000 and funding at least $1,500,000 in exploration work by December 31, 2030 [4]. - A further 15% interest can be earned by making cash payments of $300,000 and funding at least $7,500,000 in exploration work by December 31, 2032 [4]. Joint Venture and Ownership Adjustments - If Barrick does not complete the funding options, the joint venture interests will be subject to adjustments based on funding and dilution terms, with dilution below 10% converting to a 2% net smelter return royalty [5]. About the Lewis Property - The Lewis property consists of 154 exclusive exploration rights covering 86 km and is strategically located near significant geological features, including the Nelligan deposit, which has inferred resources of 106.395 million tonnes grading 0.96 g/t Au [6]. - The property is also near the former Lac Shortt mine, which historically produced 2.7 million tonnes at a grade of 4.6 g/t Au [6]. Company Overview - Midland targets mineral potential in Quebec, aiming to discover new world-class deposits of gold and critical metals, and collaborates with reputable partners including Barrick and others [7].

Core Insights - Pediatrix Medical Group, Inc. (MD) reported a third-quarter 2025 adjusted earnings per share (EPS) of 67 cents, exceeding the Zacks Consensus Estimate by 45.7% and reflecting a year-over-year increase of 52.3% [1][9] - Net revenues decreased by 3.6% year over year to $492.9 million, although this figure surpassed the consensus mark by 1.8% [1][2] Financial Performance - The quarterly results benefited from higher collection activity, improved patient acuity, a favorable payor mix, and a significant reduction in operating expenses [2] - Same-unit revenues increased by 8% year over year, outperforming the growth estimate of 3.4%, with patient volume contributing a 0.4% rise [3] - Same-unit revenues from net reimbursement-related factors grew by 7.6% year over year, driven by improved patient acuity and higher administrative fees [3] - Total operating expenses fell by 11% year over year to $424.8 million, which was lower than the estimated $425.1 million [4] - Practice salaries and benefits decreased by 8.9% year over year to $332.3 million, influenced by practice dispositions [5] - Net income reached $71.7 million, a significant increase from $19.4 million in the prior-year quarter, while adjusted EBITDA rose by 45% year over year to $87.3 million, exceeding the estimate of $59.9 million [5][9] Cash and Debt Position - As of September 30, 2025, Pediatrix Medical had cash and cash equivalents of $340.1 million, a 47.9% increase from the end of 2024 [6] - Total assets rose by 2.2% to $2.2 billion, while total debt decreased by 2.5% to $602.5 million [6] - Total shareholders' equity improved by 16.4% to $890.7 million [7] Share Repurchase Program - In the first nine months of 2025, Pediatrix Medical repurchased common shares worth $20.9 million, with a remaining capacity of $229.1 million under its $250 million repurchase program [8] Future Guidance - Management has revised the adjusted EBITDA projection for 2025 to a range of $270-$290 million, up from the previous estimate of $245-$255 million [10] - Net income is now expected to be between $155.90 million and $170.50 million, higher than the earlier guidance of $126.02-$133.32 million [10]

Core Insights - Midland Exploration Inc. and SOQUEM Inc. announced new assay results from the Malaco Mountain project, confirming the area's potential for copper, gold, and rare earth elements (REE) [3][4][12] - The exploration campaign in September 2025 involved rock sampling that yielded significant grades of copper and gold, indicating strong mineralization [4][7][9] Summary by Category Exploration Results - In June 2025, three rock samples from the Malaco Mountain project showed high grades: 31.60% Cu, 6.92 g/t Au, and 0.16% REE; 12.30% Cu, 0.36 g/t Au, and 0.57% REE; and 0.65% Cu, 0.05 g/t Au, and 0.39% REE [4][9] - A follow-up sampling campaign in September 2025 included two transects of 10 and 13 meters, collecting 25 grab samples, with the best results showing up to 27.60% Cu and 0.88 g/t Au [5][7] Mineralization Characteristics - A total of 18 samples yielded grades above 0.1% Cu, with 10 samples exceeding 1% Cu, and gold grades ranging from 61 to 877 ppb Au [9] - The mineralization is characterized by chalcopyrite and malachite in altered siltstones and mudstones, with veining observed [9] Strategic Alliance - The Strategic Alliance between Midland and SOQUEM aims to explore the Labrador Trough, with a commitment of up to $5 million over four years, including $2 million in the first two years [12] - The joint annual budget for exploration in 2025 was set at $1 million, shared equally between Midland and SOQUEM [12] Quality Control - Rock samples are analyzed at Actlabs in Ontario, employing industry-standard quality assurance and control practices [10]